Copper is indispensable to human physiology. It helps enzymes produce energy, supports antioxidant defenses, contributes to neurotransmitter production and participates in the formation and maintenance of connective tissue and blood vessels. The body normally keeps copper within a narrow range through coordinated control by the liver, bloodstream, kidneys and cells. This balance is important because copper can switch between chemical states, allowing it to participate in useful reactions but also making it capable of promoting oxidative stress when regulation fails. In excessive amounts, copper may accelerate the formation of reactive oxygen species—chemically active molecules that can damage lipids, proteins and DNA. The new research places this biological duality at the center of depression biology.

The hippocampus is particularly relevant because it is both highly active metabolically and sensitive to prolonged stress. It helps encode memories, distinguish safe from threatening situations and regulate feedback within the hypothalamic-pituitary-adrenal axis, the system that controls many hormonal responses to stress. Chronic psychological stress and depression have been associated with changes in hippocampal plasticity, including altered communication between neurons and impaired generation or survival of new cells in certain hippocampal areas. If excess copper disrupts energy production, damages cellular membranes or intensifies inflammation, it could affect the hippocampus at several levels simultaneously. These effects could help explain why disturbances in mood are often accompanied by difficulties with concentration, memory and emotional resilience.

The study’s clinical and animal design is important because each type of evidence answers a different question. Clinical research can reveal whether copper-related changes are associated with depression in people, while animal experiments can explore biological mechanisms that cannot be examined directly in patients. A relationship between copper and depressive symptoms alone would not prove that copper causes the disorder; depression can influence diet, metabolism, sleep, medication use and other factors that may also affect trace-element regulation. Animal evidence can strengthen the case for a mechanism by testing whether copper exposure or altered copper handling is accompanied by measurable changes in hippocampal function. Together, these approaches can provide a more complete picture than either one could deliver alone.

At the cellular level, copper excess could compromise hippocampal function through several overlapping pathways. Oxidative stress can impair mitochondrial activity, reducing the energy available for neurons to maintain electrical gradients and communicate across synapses. Neurons depend heavily on mitochondria because they require a continuous supply of adenosine triphosphate, or ATP, to operate ion pumps and recycle neurotransmitters. Copper-related damage may also alter the proteins that control synaptic plasticity—the ability of neural connections to strengthen or weaken in response to experience. In addition, oxidative injury can activate microglia, the brain’s resident immune cells. Persistent microglial activation may release inflammatory signals that disturb neuronal signaling and interfere with the formation of adaptive stress responses.

Copper may also intersect with systems already implicated in depression, including serotonin, dopamine, glutamate and the stress-hormone network. Copper-dependent enzymes participate in the synthesis or breakdown of several biologically important molecules, meaning that disrupted copper availability could influence chemical communication in the brain even without directly killing neurons. At the same time, excessive copper may disturb the balance between excitatory and inhibitory signaling. Too much excitatory activity, particularly through glutamatergic pathways, can place additional demands on neurons and increase vulnerability to oxidative damage. These mechanisms remain biologically plausible rather than a simple explanation for every case of depression, but they illustrate why metal homeostasis is receiving increasing attention in psychiatric research.

The findings also raise questions about how copper moves between the body and the brain. Copper in the blood is carried largely by proteins, including ceruloplasmin and albumin, and entry into the central nervous system is regulated by barriers and transport systems. The blood-brain barrier does not function as an open pipeline; it selectively controls which substances reach neural tissue. Specialized copper transporters distribute the element to cells, while other proteins bind, store or export it. If these systems become overwhelmed or dysregulated, copper could accumulate in vulnerable compartments or become chemically active in ways that are not reflected by a single routine blood measurement. This complexity means that future studies will need to distinguish total copper from its biologically available forms and examine how copper is distributed across tissues.

For patients and families, the research should not be interpreted as a recommendation to take copper supplements, avoid copper-containing foods or use unproven “metal detox” products. Copper is required for health, and deficiency can also cause serious problems. Moreover, major depressive disorder is a multifactorial condition shaped by genetics, environment, immune activity, stress exposure, sleep, physical health and social circumstances. The study does not turn depression into a single-nutrient disease, nor does it establish that correcting copper levels will prevent or cure depression. Any assessment of abnormal copper status would require appropriate laboratory testing and medical interpretation, particularly because liver disease, genetic disorders of copper metabolism, nutritional problems and certain treatments can affect copper regulation.

The potential significance of the work lies in the possibility of identifying a biological vulnerability that could complement existing approaches to diagnosis and treatment. If future research confirms that copper-related changes reliably track a particular subtype of depression or predict hippocampal dysfunction, copper metabolism could become part of a broader biomarker framework. Such a framework might combine trace-element measurements with inflammatory markers, imaging, cognitive testing and information about treatment response. Researchers could then investigate whether therapies that protect mitochondria, reduce neuroinflammation or restore normal metal handling influence depressive symptoms or hippocampal performance. Those possibilities remain prospective, but the clinical-animal strategy described in the paper provides a foundation for testing them more rigorously.

The study arrives as neuroscience increasingly moves beyond the idea that depression is explained by a single neurotransmitter imbalance. Contemporary research is examining interconnected networks involving metabolism, immunity, stress hormones, synaptic plasticity and the brain’s ability to adapt to environmental pressure. Copper fits into this wider picture because it is simultaneously a nutrient, an enzyme cofactor and a potential source of chemical stress. By focusing on the hippocampus, Zhong and colleagues connect a molecular question—how the brain handles an essential metal—to the cognitive and emotional symptoms experienced by people with depression. The next challenge will be replication: larger clinical cohorts, precise measurements of copper biology, carefully controlled animal experiments and studies that determine whether copper-related changes are a cause, a consequence or a contributing factor in major depressive disorder.

Subject of Research: The relationship between excess copper, hippocampal dysfunction and major depressive disorder, examined through clinical and animal evidence.

Article Title: Excess copper compromises hippocampal function in major depressive disorder: a study on clinical and animal evidence

Article References: Zhong, S., Chen, R., He, J. et al. “Excess copper compromises hippocampal function in major depressive disorder: a study on clinical and animal evidence.” Translational Psychiatry (2026). https://doi.org/10.1038/s41398-026-04262-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04262-5

Keywords: Excess copper, hippocampus, major depressive disorder, depression, metal homeostasis, oxidative stress, neuroinflammation, animal evidence, clinical evidence

Major depressive disorder remains one of the most challenging mental health conditions to treat effectively, with complex etiology involving genetic, biochemical, and environmental factors. A growing body of research highlights the pivotal role played by intracellular signaling cascades such as the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway in the disease’s pathophysiology. Dysregulation within this pathway, especially alterations in genes like JAK2 and STAT3, has been associated with the manifestation of depressive symptoms, making it an attractive target for novel therapeutic interventions.

The innovative edge of the present study lies in investigating selenium nanoparticles—nano-selenium—for their potential to influence this molecular pathway. Selenium itself is a trace element known for its antioxidant properties, crucial in mitigating oxidative stress that is often elevated in depressive disorders. The nanoscale formulation enhances its bioavailability and cellular uptake compared to standard selenium compounds, raising hopes for more impactful clinical outcomes.

This rigorous triple-blind, randomized controlled trial was meticulously conducted at the Psychosomatic Clinic of Imam Khomeini Hospital Complex in Iran. Fifty adults newly diagnosed with MDD were enrolled and randomized into two groups: one receiving 55 micrograms per day of nano-selenium supplementation alongside standard treatment with sertraline, and the other receiving a placebo with sertraline for a duration of 12 weeks. The triple-blind design ensured that participants, clinicians, and outcome assessors were unaware of group assignments, enhancing the reliability of the findings.

Gene expression analyses through reverse transcription quantitative polymerase chain reaction (RT-qPCR) provided precise measurements of JAK2, STAT3, and IDO1 expression levels pre- and post-intervention. IDO1, or indoleamine 2,3-dioxygenase 1, is an enzyme linked with tryptophan metabolism and inflammatory pathways, both of which are implicated in depression. Monitoring changes in these molecular markers sheds light on the biochemical responses triggered by nano-selenium supplementation.

Results revealed that both groups exhibited significant reductions in the relative gene expression of JAK2 and STAT3 over the 12-week period, indicating a general effect of standard antidepressant treatment combined with either nano-selenium or placebo. However, while the nano-selenium group showed a trend toward more pronounced reductions, these differences did not reach statistical significance when compared directly to the placebo group. The IDO1 expression changes were not significantly highlighted, suggesting the primary impact centered around JAK2 and STAT3 signaling components.

This nuanced outcome carries important implications. It suggests that nano-selenium, despite its enhanced delivery capabilities and antioxidant properties, may require further dose optimization, extended treatment duration, or perhaps combination with other therapeutic modalities to exert a strong modulatory effect on the JAK/STAT pathway. Additionally, individual biological variability and the complex nature of depression-associated molecular changes might have influenced the results.

The researchers emphasize that this is the pioneering human clinical trial examining nano-selenium’s impact on JAK/STAT signaling in MDD, providing a valuable foundation for future investigations. Their work underscores the importance of exploring nano-enabled nutraceuticals as adjunctive therapies in psychiatric conditions, which may one day augment or refine existing pharmacological treatments with fewer side effects or enhanced efficacy.

Moreover, the elucidation of how antioxidants like selenium nanoparticles can alter intracellular signaling adds a new dimension to depression research. It intersects with emerging theories on neuroinflammation, oxidative stress, and neurotransmitter metabolism in MDD, highlighting the complexity of underlying mechanisms and the need for multi-targeted therapeutic approaches.

Future research directions prompted by this study include increasing sample sizes to enhance statistical power, testing varying dosages, and examining longer intervention periods. Additionally, integrating comprehensive behavioral and neurocognitive assessments alongside molecular analyses would help clarify the clinical significance of gene expression modulation observed here.

The ethical rigor and transparent trial registration, approved by the Iran University of Medical Sciences and registered with the Iranian Registry of Clinical Trials, further strengthen the credibility and reproducibility of the findings. These procedural details contribute to the trustworthiness of the data and offer a template for subsequent studies in this domain.

In summary, this pioneering work marks a significant step forward in merging nanotechnology with psychiatric treatment strategies, representing hope for more targeted, mechanism-based therapies for major depression. As our molecular understanding deepens, nanoformulations like selenium nanoparticles may evolve from experimental adjuncts into mainstream components of personalized mental health care.

Subject of Research: Modulation of the JAK/STAT signaling pathway in major depressive disorder through nano-selenium supplementation.

Article Title: Impact of Nano-Selenium supplementation on the JAK/STAT signaling pathway in major depressive disorder: a Triple-Blind, randomized controlled trial.

Article References:
Noormohammadi, M., Etesam, F., Amini, A. et al. Impact of Nano-Selenium supplementation on the JAK/STAT signaling pathway in major depressive disorder: a Triple-Blind, randomized controlled trial. BMC Psychiatry 25, 785 (2025). https://doi.org/10.1186/s12888-025-07213-4

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07213-4

Depression, a multifactorial and heterogenous psychiatric disorder, has long defied one-size-fits-all treatment paradigms. Traditional pharmacotherapies often center on monoamine modulation but fall short for many patients, highlighting the urgency for novel approaches that address the disorder’s underlying pathophysiology. The recent work by Wang, Chen, Zhong, and colleagues harnesses insights from traditional medicinal practices, focusing on Ershiwei Roudoukou—a herbal formulation historically acclaimed in Eastern medicine for alleviating mood disorders. Their investigation zeroes in on Macelignan, a bioactive compound isolated from the pills, known for its antioxidant and anti-inflammatory properties, to discern its role within the neurobiological landscape of depression.

Central to the study is the recognition that oxidative stress plays a pivotal role in depression pathogenesis, a notion increasingly supported by accumulating biochemical and clinical evidence. Oxidative stress arises when reactive oxygen species (ROS) overwhelm cellular antioxidant defenses, leading to damage in neuronal structures and disruptions in neurotransmission. The researchers demonstrated that administration of Ershiwei Roudoukou pills—and Macelignan specifically—effectively mitigated markers of oxidative damage in key brain regions implicated in mood regulation, such as the prefrontal cortex and hippocampus. The antioxidative action not only curbed neuronal injury but also appeared to restore redox homeostasis, which is critical for proper synaptic function.

Neuroinflammation represents another cornerstone in the psychopathology of depression. Chronic, low-grade inflammation within the central nervous system perpetuates neuronal dysfunction through cytokine release, microglial activation, and ensuing neurotoxic cascades. The investigation revealed that treatment with Ershiwei Roudoukou and Macelignan significantly suppressed pro-inflammatory cytokine expression, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), thereby dampening neuroinflammatory pathways. This suppression not only alleviated inflammatory burden but also conferred neuroprotective benefits, fostering an environment conducive to neuronal survival and function.

Perhaps the most compelling aspect of this study lies in its exploration of synaptic plasticity modulation. Synaptic plasticity—the brain’s capacity to reorganize neural connections dynamically—is essential for mood regulation, learning, and memory. Depression is characterized by synaptic deficits and altered neuroplasticity, often reflected in reduced dendritic spine density and impaired long-term potentiation. The authors provide evidence that the Macelignan compound enhances synaptic plasticity markers by upregulating brain-derived neurotrophic factor (BDNF) and promoting synaptic protein synthesis in neuronal cultures and animal models. These changes potentially underpin the observed antidepressant-like behavioral improvements, as increased plasticity translates to enhanced neural circuit adaptability.

From a mechanistic standpoint, the study deftly integrates molecular biology techniques—including immunohistochemistry, enzyme-linked immunosorbent assays (ELISA), and Western blot analysis—to chart the biochemical shifts engaged by Ershiwei Roudoukou and its active ingredient. Notably, these methodologies unveiled the modulation of nuclear factor erythroid 2–related factor 2 (Nrf2) signaling pathways, a master regulator of antioxidant response. By activating Nrf2, the compounds enhance the expression of endogenous antioxidant enzymes such as heme oxygenase-1 (HO-1), catalase, and superoxide dismutase, collectively orchestrating cellular defense against oxidative insult.

Moreover, the suppression of the nuclear factor-kappa B (NF-κB) pathway—a central mediator of inflammation—was markedly evident following treatment. This transcription factor regulates the expression of multiple inflammatory cytokines and adhesion molecules, heightening neuroinflammatory states. The blockade of NF-κB activation by Macelignan points to its potential role in curtailing persistent neuroimmune activation implicated in depression’s chronicity. Such dual regulatory effects on oxidative and inflammatory pathways underscore the therapeutic versatility of the compounds.

Behavioral assessments conducted in validated animal models of depression further substantiated the biochemical findings. Rodents treated with Ershiwei Roudoukou pills or isolated Macelignan showed significant reductions in immobility times in the forced swim and tail suspension tests, classical paradigms used to evaluate antidepressant activity. Additionally, these animals exhibited improved performance in cognitive tasks sensitive to hippocampal integrity, such as the novel object recognition test, suggesting benefits beyond mood alleviation.

The translational implications of these discoveries are profound. As depression’s heterogeneity challenges conventional therapies, multimodal agents targeting oxidative stress, neuroinflammation, and synaptic plasticity offer a promising new therapeutic avenue. The potential for Ershiwei Roudoukou and Macelignan to act synergistically on these interlinked pathological domains could revolutionize treatment strategies, shifting focus from neurotransmitter-centric models to integrative neurobiological frameworks.

Importantly, the safety profile elucidated in preclinical studies is encouraging. No significant toxicological concerns were reported at therapeutic dosages, and the natural origin of the compounds may offer advantages in adherence and tolerability. However, the authors prudently emphasize the necessity of rigorous clinical trials to evaluate efficacy, pharmacokinetics, and long-term safety in human populations before clinical adoption.

Beyond depression, the antioxidative and anti-inflammatory mechanisms revealed suggest broader applicability in neuropsychiatric and neurodegenerative disorders where similar pathologies converge. This positions Ershiwei Roudoukou and Macelignan as candidates for further investigation in conditions such as anxiety, bipolar disorder, and even Alzheimer’s disease, heralding a new generation of botanical-derived neurotherapeutics.

From a scientific perspective, the integration of traditional medicine with cutting-edge molecular techniques exemplifies a burgeoning trend in psychopharmacology. It exemplifies how ancient herbal remedies, once marginalized in Western medicine, can be systematically validated and optimized through the lens of modern neuroscience. The detailed mechanistic insights presented in this study set a benchmark for future research exploring ethnobotanical compounds in mental health.

In conclusion, the elucidation of Ershiwei Roudoukou pills and Macelignan’s antidepressant effects via attenuation of oxidative stress, suppression of neuroinflammation, and enhancement of synaptic plasticity opens promising therapeutic frontiers. This multi-target approach addresses key determinants of depressive pathology, potentially overcoming limitations inherent to current monoaminergic drugs. As the global burden of depression continues to escalate, such innovative strategies grounded in natural bioactives may herald a paradigm shift in how mental illness is understood and treated, blending time-honored wisdom with scientific rigor to yield impactful clinical advancements.

Subject of Research: Antidepressant effects of Ershiwei Roudoukou pills and their active ingredient Macelignan, particularly focusing on oxidative stress, neuroinflammation, and synaptic plasticity mechanisms.

Article Title: Antidepressant effects of Ershiwei Roudoukou pills and its active ingredient Macelignan: Multiple mechanisms involving oxidative stress, neuroinflammation and synaptic plasticity.

Article References:
Wang, YL., Chen, L., Zhong, XL. et al. Antidepressant effects of Ershiwei Roudoukou pills and its active ingredient Macelignan: Multiple mechanisms involving oxidative stress, neuroinflammation and synaptic plasticity. Transl Psychiatry 15, 163 (2025). https://doi.org/10.1038/s41398-025-03378-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03378-4